• ExpreS2ion has completed enrollment in its Phase I ES2B-C001 trial, with all 19 patients with advanced breast cancer starting treatment.
• Primary results are now expected in the first quarter of 2027, rather than year-end 2026.
• Preliminary results released October 23 showed anti-HER2 antibody responses in most evaluable patients.
• No dose-limiting toxicities or serious adverse events considered related to ES2B-C001 were reported.
• Phase II initiation remains targeted for the second half of 2027; trial design depends on partner input, regulatory discussions and financing.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ExpreS2ion Biotech Holding AB published the original content used to generate this news brief on October 23, 2026, and is solely responsible for the information contained therein.